The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant

C Justenhoven; O Obazee; S Winter; FJ Couch; JE Olson; P Hall; U Hannelius; J Li; K Humphreys; G Severi; G Giles; M Southey; L Baglietto; PA Fasching; MW Beckmann; AB Ekici; U Hamann; C Baisch; V Harth; S Rabstein; A Lotz; B Pesch; T Brüning; YD Ko; H Brauch

Journal article

The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant

C Justenhoven, O Obazee, S Winter, FJ Couch, JE Olson, P Hall, U Hannelius, J Li, K Humphreys, G Severi, G Giles, M Southey, L Baglietto, PA Fasching, MW Beckmann, AB Ekici, U Hamann, C Baisch, V Harth, S Rabstein Show all

Breast Cancer Research and Treatment | SPRINGER | Published : 2012

DOI: 10.1007/s10549-011-1827-1

University of Melbourne Researchers

Graham Giles Author

Melissa Southey Author

Related Projects (2)

PLATYPUS

This proposal builds on the applicants’ experience with existing large prospective studies and on studies of families of patients with bowel..

Epidemiology of chronic disease, health interventions and DNA studies

Grants

Awarded by National Institutes of Health

Citation metrics

5Scopus

5Web of Science

5Dimensions

Keywords

3211 Oncology and Carcinogenesis

Metabolism

Randomized Controlled-Trial

Breast Cancer

32 Biomedical and Clinical Sciences

Oncology

Aging

Estrogen Plus Progestin

Life Sciences & Biomedicine